Buscar
Mostrando ítems 1-10 de 1281
Randomized trials addressing a similar question are commonly published after a trial stopped early for benefit
(Elsevier, 2017)
Objective: We explored how investigators of ongoing or planned trials respond to the publication of a trial stopped early for benefit addressing a similar question. Study Design and Setting: We searched multiple databases ...
Improving representativeness in trials: a call to action from the Global Cardiovascular Clinical Trialists Forum
(Oxford University Press, 2023)
Participants enrolled in cardiovascular disease (CVD) randomized controlled trials are not often representative of the population living with the disease. Older adults, children, women, Black, Indigenous and People of ...
Initiation and continuation of randomized trials after the publication of a trial stopped early for benefit asking the same study question: STOPIT-3 study design
(BioMed Central, 2013)
Background: Randomized control trials (RCTs) stopped early for benefit (truncated RCTs) are increasingly common and, on average, overestimate the relative magnitude of benefit by approximately 30%. Investigators stop trials ...
Twenty-two years’ experience registering trials in a low-middle income country: The Peruvian Clinical Trial Registry
(Blackwell Publishing Inc., 2019)
Aim: This study analyzes the quantitative and qualitative evolution of the Peruvian Clinical Trial Registry during the last 22 years. Methods: Following a cross-sectional design, we reviewed all clinical trials registered ...
Twenty-two years’ experience registering trials in a low-middle income country: The Peruvian Clinical Trial Registry
(Blackwell Publishing Inc., 2019)
Aim: This study analyzes the quantitative and qualitative evolution of the Peruvian Clinical Trial Registry during the last 22 years. Methods: Following a cross-sectional design, we reviewed all clinical trials registered ...
Questioning clinical trialsInterpelando a los ensayos clínicos
(Universidad Nacional de Lanús, 2011)
Incorporating Cultural Competence and Cultural Humility in Cardiovascular Clinical Trials to Increase Diversity Among Participants
(Elsevier, 2022)
The Problem of Homogeneity Among RCT Participants Despite recommendations for the inclusion of diverse racial and ethnic groups by federal grant and regulatory agencies, cardiovascular trial populations remain predominantly ...
Tocilizumab in COVID-19: Enthusiasm vs. evidence
(Wolters Kluwer Health, 2021)
Based on the pathophysiological characterization of COVID-19, initial studies suggested the use of tocilizumab (TCZ), a recombinant humanized monoclonal antibody of the immunoglobulin G1 class, for management of the cytokine ...